A record of what Arun Kejriwal said publicly, with the source. Not advice.
Pending — not yet graded
“Advises investors to apply for the Anthem Biosciences IPO, citing the company's strong CRDMO operations, healthy net margins of 23.4%, and a PAT of ₹451 crores for FY25. A key comforting factor is the promoter founder retaining over 52% stake and not selling any shares in this entirely offer-for-sale issue.”
Anthem BiosciencesBullishCalled 14 Jul 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Arun Kejriwal’s full track record